pmaurya
Narcolepsy Market Insight, Epidemiology, and Market Forecast Analysis Report
What is Narcolepsy?
Narcolepsy is a chronic neurological/brain disorder which involves poor control of sleep and wakefulness.
Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. People suffering from narcolepsy experience periods of excessive daytime sleepiness and sudden uncontrollable episodes of falling asleep during any time of the day.
How is Narcolepsy caused?
Narcolepsy is classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1), formerly Narcolepsy with cataplexy caused by a selective loss of hypothalamic neurons producing hypocretin, and narcolepsy type 2 (NT2), formerly Narcolepsy without cataplexy and with normal hypocretin levels.
How is Narcolepsy treated?
There is no curative therapy for Narcolepsy till date, and current recommended therapies in Narcolepsy are limited to symptomatic treatment, targeting the main Narcolepsy symptoms, depending on their severity. Behavioral and psychosocial interventions also impact the clinical outcomes of patients significantly. Various therapies have been approved by the USFDA and EMA as first and second-line Narcolepsy treatment options.
How has Narcolepsy affected population?
•The total prevalent population of Narcolepsy in seven major markets was 499,888 in 2017.
To know more, request sample pages @ www.delveinsight.com/sample-request/narcolepsy-market
Narcolepsy Market
According to DelveInsight, the market size of Narcolepsy is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets (in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan), the United States accounted for the largest Narcolepsy market size. Among the EU5 countries, Germany had the largest market size, with USD 131.90 million, followed by the United Kingdom with USD 87.93 million in 2017. Italy had the smallest market size of Narcolepsy, with USD 14.66 million in 2017.
What are the Narcolepsy market drivers?
Shortcomings associated with existing treatment, active clinical pipeline, increasing prevalence of disease are the Narcolepsy market drivers.
What are the Narcolepsy market barriers?
Need for better treatment practices, hurdles in treatment selection, identification of initial symptoms are the Narcolepsy market barriers.
Which are the leading companies in Narcolepsy market?
Key Players such as Avadel Pharmaceuticals, Axsome Therapeutics are the leading companies in Narcolepsy market.
Request sample pages for more information on www.delveinsight.com/sample-request/narcolepsy-market
Narcolepsy Market Insight, Epidemiology, and Market Forecast Analysis Report
What is Narcolepsy?
Narcolepsy is a chronic neurological/brain disorder which involves poor control of sleep and wakefulness.
Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. People suffering from narcolepsy experience periods of excessive daytime sleepiness and sudden uncontrollable episodes of falling asleep during any time of the day.
How is Narcolepsy caused?
Narcolepsy is classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1), formerly Narcolepsy with cataplexy caused by a selective loss of hypothalamic neurons producing hypocretin, and narcolepsy type 2 (NT2), formerly Narcolepsy without cataplexy and with normal hypocretin levels.
How is Narcolepsy treated?
There is no curative therapy for Narcolepsy till date, and current recommended therapies in Narcolepsy are limited to symptomatic treatment, targeting the main Narcolepsy symptoms, depending on their severity. Behavioral and psychosocial interventions also impact the clinical outcomes of patients significantly. Various therapies have been approved by the USFDA and EMA as first and second-line Narcolepsy treatment options.
How has Narcolepsy affected population?
•The total prevalent population of Narcolepsy in seven major markets was 499,888 in 2017.
To know more, request sample pages @ www.delveinsight.com/sample-request/narcolepsy-market
Narcolepsy Market
According to DelveInsight, the market size of Narcolepsy is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets (in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan), the United States accounted for the largest Narcolepsy market size. Among the EU5 countries, Germany had the largest market size, with USD 131.90 million, followed by the United Kingdom with USD 87.93 million in 2017. Italy had the smallest market size of Narcolepsy, with USD 14.66 million in 2017.
What are the Narcolepsy market drivers?
Shortcomings associated with existing treatment, active clinical pipeline, increasing prevalence of disease are the Narcolepsy market drivers.
What are the Narcolepsy market barriers?
Need for better treatment practices, hurdles in treatment selection, identification of initial symptoms are the Narcolepsy market barriers.
Which are the leading companies in Narcolepsy market?
Key Players such as Avadel Pharmaceuticals, Axsome Therapeutics are the leading companies in Narcolepsy market.
Request sample pages for more information on www.delveinsight.com/sample-request/narcolepsy-market